Navigation Links
Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference
Date:12/12/2011

ss release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and synthetic vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable synthetic vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can
'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing
2. Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
3. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
4. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
5. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
6. Inovio Pharmaceuticals Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
7. Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines Potential to Help Ensure Nations Food Supply Safety
8. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
9. Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
10. Inovio Pharmaceuticals to Present at Investor Conferences
11. Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... American Association of Diabetes Educators, American Diabetes ... A. Menarini, Bayer Group, Bayer Healthcare, BioTex, ... Medicare and Medicaid Services ( USA ... Prevention (CDC), Carlyle Group, Cascade Metrix Inc., ... ConvaTec, Constitution Medical Investor, Dexcom, Diabetes UK, ...
(Date:3/1/2015)... 2015  An innovative interventional radiology treatment has ... relief of their headaches, according to research being ... ,s Annual Scientific Meeting . Clinicians at ... York Empire State College in Saratoga Springs used ... blocks to give patients enough ongoing relief that ...
(Date:2/27/2015)... , Feb. 27, 2015 Roughly ... or very confident substituting an interchangeable biosimilar for ... share the same nonproprietary name, according to a ... Pharmacy,s (AMCP,s) Journal of Managed Care & ... about 25 percent of pharmacists would feel as ...
Breaking Medicine Technology:Blood Glucose Meters Industry 2019 Forecasts for Global and Chinese Regions 2Image-guided treatment shown to break the migraine cycle 2Image-guided treatment shown to break the migraine cycle 3Image-guided treatment shown to break the migraine cycle 4Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2
... , PISCATAWAY, N.J., Dec. 1 ... of hearing instruments, announced its third annual partnership with Quota ... September 2010. , As part of the renewed partnership, Siemens ... hearing instruments to both children and young adults, age 23 ...
... , ... Board: CBPO) (Nasdaq: CBPO ) ("China Biologic," or,the "Company"), one ... Company has received approval to list its,common stock on the NASDAQ ... shares to begin trading on the NASDAQ on,Wednesday, December 2, 2009, ...
Cached Medicine Technology:Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 3China Biologic Products Approved to List on NASDAQ 2China Biologic Products Approved to List on NASDAQ 3
(Date:3/2/2015)... 2015 After a rigorous evaluation process ... pricing and long-term strategy, Blood Centers of America (BCA) ... for member centers’ testing needs. , BCA, which comprises ... than 30 percent of the U.S. blood supply, made ... is committed to drive cost savings to members,” said ...
(Date:3/2/2015)... March 02, 2015 Representatives with ... has officially launched a multivitamin supplement that’s specifically ... product development for BNatrl, said the multivitamin, which ... Olympic and other world-class athletes. , "Being an ... this pure whole food multivitamin to improve my ...
(Date:3/2/2015)... Washington, DC (PRWEB) March 02, 2015 ... the publication of AIS’s Directory of Health Plans: ... comprehensive resource available on the U.S. health plan market, ... operating in the United States. , Available as ... “Executive Summary” of enrollment trends in quick-view tables and ...
(Date:3/2/2015)... What are the best practices for writing ... are interviews scheduled, how can physicians best prepare, and ... practicing physicians who are looking for new opportunities can ... the PracticeLink Physician Career Advancement Workshop and Job Fair ... from 5:30 to 8:30 p.m. at the Marriott-Texas Medical ...
(Date:3/2/2015)... Final Cut Pro X plugin specialists have ... Film Studios. , “The TranStatic Volume 2 plugin gives users ... CEO of Pixel Film Studios. “TranStatic Volume 2 is a ... editors toolbox.” , With TranStatic Volume 2 users can transition ... scrambling effects from Pixel Film Studios. Users have total control ...
Breaking Medicine News(10 mins):Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 3Health News:Bnatrl Launches Multivitamin Supplement for Runners 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2
... , HOUSTON , Feb. 8 Runners and ... to visit the NASA Goes the Distance exhibit this Friday and ... Palmer Event Center. NASA,s exhibit will be open from 3 ... to 6 p.m. Saturday . The exhibit will be located in ...
... matter unless father was older, mom much younger, study found ... more likely to have a child with autism than women ... , Researchers from University of California, Davis, looked at records ... and 1999, a decade in which autism incidence increased 600 ...
... ... Shawn Strash, FACHE, Chief Executive Officer with Oro Valley Hospital, on critical issues facing ... ... foster timely communication among different segments of the medical community, Jackson & Coker ( ...
... , , , , , ... Feb. 8 /PRNewswire-Asia-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink Sheet: ... botanical products,bio-pharmaceuticals and traditional Chinese medicines ("TCM"), announced today,that it ... fiscal year ended, October 31, 2009 on time. In ...
... ... joins StatCom in a strategic partnership program that helps hospitals transform throughput operations. ... Atlanta, GA (PRWEB) ... MSN, FACHE, a former Trident Health System executive, to the StatCom transformation team as ...
... limiting TV and getting enough sleep cut risk of obesity, ... as simple as sitting down to dinner together as a ... fend off obesity. , That,s just one of the findings ... a significant impact on the weight of preschool children. Other ...
Cached Medicine News:Health News:NASA Joins Austin Marathon Expo, Inspires Students 2Health News:Older Moms More Apt to Have Autistic Child 2Health News:Older Moms More Apt to Have Autistic Child 3Health News:Jackson & Coker Industry Report Spotlights Healthcare Executive Interview, 2Health News:Jackson & Coker Industry Report Spotlights Healthcare Executive Interview, 3Health News:Jackson & Coker Industry Report Spotlights Healthcare Executive Interview, 4Health News:Jackson & Coker Industry Report Spotlights Healthcare Executive Interview, 5Health News:Jackson & Coker Industry Report Spotlights Healthcare Executive Interview, 6Health News:Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements 2Health News:Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements 3Health News:PJ Johnson Joins StatCom as Enterprise VP, Southeast Region 2Health News:PJ Johnson Joins StatCom as Enterprise VP, Southeast Region 3Health News:3 Home Habits Help Youngsters Stay Slim 2Health News:3 Home Habits Help Youngsters Stay Slim 3
... TBR-40 is a small bench style refrigerator (can ... only a minimum number of bags is to ... External cabinet finish is white colorbond steel while ... closing side hinged glass door is key lockable. ...
... refrigerator is specially designed ... blood in standard 500ml ... Standard AS3864 1997. Quiet ... utilising CFC Free refrigerant ...
The Testosterone Enzyme Immunoassay is intended for the quantitative determination of Testosterone concentration in human serum. No special pretreatment of the sample is necessary. For in vitro Diag...
The Testosterone ELISA is intended for the quantitative determination of testosterone concentration in human serum. No special pretreatment of the sample is necessary....
Medicine Products: